信达生物玛仕度肽Ⅲ期临床试验达主要终点;康哲药业与诺华签订独家经销协议 | 医药早参

每日经济新闻
Oct 28

丨 2025年10月28日星期二丨  NO.1 信达生物玛仕度肽Ⅲ期临床试验达主要终点  10月27日,信达生物宣布自主研发的GCG/GLP-1双受体激动剂玛仕度肽在Ⅲ期临床试验DREAMS-3中达成主要终点。在中国2型糖尿病合并肥胖患者中,玛仕度肽在血糖控制与体重管理的综合疗效显著优于司美格鲁肽,并在空腹血糖、腰围、收缩压、甘油三酯等多项心血管代谢风险因素上展现出更优改善效果。  点评:相比...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10